Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
MP3•בית הפרקים
Manage episode 448060893 series 3381434
תוכן מסופק על ידי ReachMD. כל תוכן הפודקאסטים כולל פרקים, גרפיקה ותיאורי פודקאסטים מועלים ומסופקים ישירות על ידי ReachMD או שותף פלטפורמת הפודקאסט שלהם. אם אתה מאמין שמישהו משתמש ביצירה שלך המוגנת בזכויות יוצרים ללא רשותך, אתה יכול לעקוב אחר התהליך המתואר כאן https://he.player.fm/legal.
CME credits: 0.25
Valid until: 31-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/empowering-choices-navigating-early-stage-hr-her2-breast-cancer-with-cdk46-inhibition/26643/
Hormone receptor-positive, HER2-negative cancer is the most common subtype of breast cancer. Initial treatment consists of surgery with or without radiotherapy or chemoradiotherapy, followed by adjuvant endocrine therapy for 5 to 10 years. Although endocrine therapy improves outcomes in these patients, recurrence is high (40% to 60% of patients). In disease with no BRCA mutation, treatment intensification by adding a CDK4/6 inhibitor to endocrine therapy has been shown to improve survival outcomes in high-risk disease. This activity explores the role of CDK4/6 inhibitors in HR-positive, HER2-negative early breast cancer in a patient case vignette, with an emphasis on shared decision-making. =
…
continue reading
Valid until: 31-10-2025
Claim your CME credit at https://reachmd.com/programs/cme/empowering-choices-navigating-early-stage-hr-her2-breast-cancer-with-cdk46-inhibition/26643/
Hormone receptor-positive, HER2-negative cancer is the most common subtype of breast cancer. Initial treatment consists of surgery with or without radiotherapy or chemoradiotherapy, followed by adjuvant endocrine therapy for 5 to 10 years. Although endocrine therapy improves outcomes in these patients, recurrence is high (40% to 60% of patients). In disease with no BRCA mutation, treatment intensification by adding a CDK4/6 inhibitor to endocrine therapy has been shown to improve survival outcomes in high-risk disease. This activity explores the role of CDK4/6 inhibitors in HR-positive, HER2-negative early breast cancer in a patient case vignette, with an emphasis on shared decision-making. =
454 פרקים